Hendrick Motorsports is proposing a $35 million investment to develop a 260,000-square-foot manufacturing facility adjacent to its Concord campus.

The Charlotte Business Journal reports that the town has proposed incentives for the project, which are valued at $124,950.

The facility is expected to be developed on a 27-acre site at 4295 Defender Way NW in Concord. The site is less than two miles from Charlotte Motor Speedway.

Assuming the project moves forward, it would join two other recent advanced manufacturing investments from Hendrick Motorsports in Concord.

The first project, announced in January 2023, called for a $15 million investment. Hendrick was also plotting a speculative advanced manufacturing facility of 269,500 square feet. The city also incentivized the project, which appears to be similar to the most recent proposal.

Virco Manufacturing, a supplier of furniture and equipment for K-12 schools, has signed a multi-year renewal of its 559,000-square-foot space in the Prologis-owned 2027 Harpers Way in Torrance. It represents the first lease renewal for The Klabin Company/CORFAC International that involves the installation of solar panels for a client’s energy consumption. The panels are set to be installed next year.

The Klabin Company’s Frank Schulz III represented Prologis in the 65-month lease transaction. Virco was represented by David Prior and Todd Taugner of The Klabin Company. Virco will maintain its L.A.-area headquarters at the facility set on more than 23.5 acres near the intersection of Van Ness Avenue and Del Amo Boulevard in the heart of the South Bay industrial market.

“Due to Prologis’ incredible commitment to its customers, we were able to structure this lease for Virco to keep them in this location for years to come without any disruption to its operations,” said Prior.

Takeda has broken ground on a $230-million expansion of its Los Angeles production facility. It’s the Japanese pharmaceutical company’s largest plasma fractionation site globally, and the expansion is expected to increase production by two million liters annually.

The expansion will repurpose an existing building and site infrastructure, a move that Takeda believes will significantly reduce the time typically required for planning and permitting new construction. Additionally, the company said it will be able to minimize the environmental impact associated with new construction, reducing waste and promoting responsible resource management.

“The U.S. is playing a critical role in our global manufacturing network and contributing to our supply chain resilience globally,” said Thomas Wozniewski, global manufacturing & supply officer at Takeda. He added that the increased manufacturing capacity at the LA facility will enable Takeda “to produce more plasma-derived therapies for patients in need.”

Colliers has announced the completion of 135,600 square feet of purpose-built GMP/advanced manufacturing space in Canton, MA. The project was led by Jumbo Capital Inc. and certain funds affiliated with Apollo Global Management, with a Colliers team, including Kevin Hanna and Kevin Brawley, seeking a new tenant on behalf of the owners. 

Situated on nearly 10 acres near I-93, the property at 30 Dan Road offers a core and shell construction with features like 34-foot clear heights, four loading docks, and 6,400 amps of power. The building is subdividable to 50,000 square feet and is located within the manufacturing corridor of Canton Commerce Center, providing access from Greater Boston and Cambridge. 

“This purpose-built space is an opportunity to lease a top-of-the-line facility in a highly accessible and thriving corridor,” said Hanna. “The acquisition, conversion and expansion of this property will help meet the dynamic needs of advanced manufacturing tenants by offering space that aligns seamlessly with the sector’s expanding footprint.” The property underwent significant redevelopment back in July 2022. 

Hear from experts at the Connect Industrial Midwest 2024 event on March 5 at Joe’s Live in Rosemont, Illinois. Click here for more information and to register. 

Global biopharmaceutical firm AstraZeneca is investing $300 million in an 84,000-square-foot manufacturing facility in Rockville, MD to launch its cell therapy platforms in the U.S. for critical cancer trials and future commercial supply. Located at 9950 Medical Center Dr., it is expected to become operational in 2026.

More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas.

The Rockville facility is located less than five miles from one of the company’s five global R&D centers and sits within the life sciences corridor in Maryland. The company recently signed a full-building lease in Gaithersburg.

Maryland Gov. Wes Moore said: “AstraZeneca and the State of Maryland share a deep commitment to innovation. It makes us the perfect pairing for this next-generation cell therapy facility. This significant investment in our life sciences sector will help maintain Maryland’s leadership in the industry and sharpen our competitive edge.”